Ex-ImClone boss takes top job at Bill Gates-backed startup

Dan Lynch, the former CEO and financial chief of ImClone Systems (acquired by Eli Lilly), has taken the executive chairman job at the Cambridge, MA-based biotech startup Nimbus Discovery. He's taking over the role from Bruce Booth, a Nimbus co-founder and partner at Atlas Venture, who is remaining on the company's board. Lynch previously served as executive chairman of two Atlas-backed biotechs, Avila Therapeutics and Stromedix, which were acquired this year by Celgene ($CELG) and Biogen Idec ($BIIB), respectively. Nimbus focuses on software-enabled discovery of drugs for cancer and inflammation. Gates Ventures, an investment vehicle for Microsoft ($MSFT) Chairman Bill Gates, is an investor in Nimbus. Item

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.